INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion to Present at the Barclays Global Healthcare Conference
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15
View HTML
Toggle Summary Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018
February 28, 2018 is the 11 th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the kidneys NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement alternative pathway, today announced that the European Medicines Agency (EMA) Committee
View HTML
Toggle Summary Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results
Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief Operating Officer, promoted to President of Achillion Achillion seeking to generate additional datasets
View HTML
Toggle Summary Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at the Leerink Partners 7 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
  NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today announced that the Company has begun dosing subjects in a
View HTML
Toggle Summary Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
- Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) — - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers— NEW HAVEN, Conn., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,
View HTML
Toggle Summary Achillion Announces Pricing of Secondary Offering Of Common Stock
NEW HAVEN, Conn., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc.
View HTML
Toggle Summary Achillion Announces Proposed Secondary Offering of Common Stock
NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced that Johnson & Johnson Innovation-JJDC, Inc. ("JJDC"), an existing stockholder of Achillion, intends to offer for sale in an underwritten public offering 18,367,346 shares
View HTML
Toggle Summary Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
- Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471 - - Improvement in complement alternative pathway biomarkers observed - NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML